This segment focuses on the research, development, and commercialization of medications for the treatment of OUD. Key products include SUBLOCADE, an extended-release buprenorphine injection, and SUBOXONE sublingual film. Research and development efforts are focused on improving the efficacy and delivery of buprenorphine-based treatments, as well as exploring new formulations and treatment options. The segment utilizes advanced pharmaceutical technologies and methodologies to ensure product quality and patient safety. The patient impact is significant, as these medications help reduce opioid cravings and withdrawal symptoms, improving patient outcomes and reducing the risk of relapse. Indivior holds a strong market position in the OUD treatment space, with a focus on innovation and patient-centric care. Future opportunities include expanding access to treatment and developing new therapies for co-occurring disorders. Regulatory and clinical aspects are critical, with a focus on obtaining and maintaining FDA approvals and adhering to strict manufacturing standards. Partnerships and collaborations with healthcare providers and patient advocacy groups are essential for ensuring patient access and support.

This segment is dedicated to the development and commercialization of treatments for schizophrenia and related mental health disorders. The primary focus is on developing and marketing innovative therapies to address the unmet needs of patients suffering from schizophrenia. Research and development activities include clinical trials to evaluate the safety and efficacy of new drug candidates. The segment utilizes advanced pharmaceutical technologies and methodologies to ensure product quality and patient safety. The patient impact is significant, as these medications help reduce symptoms and improve the quality of life for patients with schizophrenia. Indivior aims to establish a strong market position in the schizophrenia treatment space by focusing on innovation and patient-centric care. Future opportunities include expanding the product portfolio and exploring new treatment modalities. Regulatory and clinical aspects are critical, with a focus on obtaining and maintaining FDA approvals and adhering to strict manufacturing standards. Partnerships and collaborations with healthcare providers and patient advocacy groups are essential for ensuring patient access and support.